BioMedReports (www.biomedreports.com) just released a summary of their FDA and Clinical Trial Calendars - which gives an update on some of the advances made in the cancer drug realm. Although, it's marketed as an investment tool - and it isn't free, it serves as a nice primer for those who may be interested in investigating the developments further.

Their FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions to the FDA for complete response rulings by the agency which require more information before an approval can be granted.

Full article: http://biomedreports.com/articles/most-popular/1098-fda-clinical-trial-c...